UTICA, NY, Aug 26, 2011 (MARKETWIRE via COMTEX) --

CONMED Corporation's (NASDAQ: CNMD) CONMED Linvatec arthroscopy unit announced today the release of its New GENESYS(TM) Matryx(R) Biocomposite Interference Screw. The new interference screws represent the latest advancement in biocomposite material technology through a proprietary microfiltration process. This process allows CONMED Linvatec to produce one of the smallest biocomposite interference screws available on the market today for primary fixation of ACL and PCL grafts.

Interference screw fixation is frequently used in the reconstruction of a failed anterior or posterior cruciate ligament of the knee. The placement of the screw and ligament into the bone tunnel allows the tissue to be held in place and encourages natural healing of the ligament. The GENESYS Matryx Interference Screw facilitates bone formation due to the presence of the bone pre-cursor Beta TriCalcium Phosphate, resulting in bone reconstruction and integration of the replacement ligament.

While the GENESYS Matryx Interference Screws are indicated for soft tissue fixation in ACL and PCL reconstructions, the smaller diameter screws are also indicated for reattachment of soft tissue to bone providing versatility for repair in other areas of the body.

"The important advancements we have made in biomaterials technology have enabled us to be first to market with one of the smallest available biocomposite interference screws for primary fixation in ACL and PCL reconstructions," said Joseph Darling, President of CONMED Linvatec. "We continue to leverage our extensive expertise in biomaterials to deliver a broad range of customer solutions that may help improve patient outcomes."

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company's products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company's 3,400 employees distribute its products worldwide from several manufacturing locations.

Forward-Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; and/or (vii) the Company's ability to devise and execute strategies to respond to market conditions.

CONTACTS:

CONMED Corporation
Investors:
Robert Shallish
Chief Financial Officer
315-624-3206

FD
B. Ritchie
212-850-5600

SOURCE: CONMED Corporation